Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

CAR-T as a salvage treatment in polyrefractory RA.

Rheumatology (Oxford, England)·2026
Same author

Comparative and Critical Analysis of Immune-based Combinations for First-line Treatment of Metastatic Renal Cell Carcinoma.

Clinical genitourinary cancer·2026
Same author

Augmented Reality Based 3D Modelling for Sentinel Lymph Node Localization in Cutaneous Melanoma: A Pilot Study.

Journal of surgical oncology·2026
Same author

Vulvar and Vaginal Melanoma: Real-world Clinical Outcomes and Prognostic Differences From a Single-center Experience.

Journal of lower genital tract disease·2026
Same author

Engineered mRNA backbones for gene expression in human T cells.

Molecular therapy. Nucleic acids·2026
Same author

Anti-CD19 CAR-T cell therapy as rescue treatment in systemic sclerosis relapsing after autologous haematopoietic stem cell transplantation: a case series.

Rheumatology (Oxford, England)·2026

Related Experiment Video

Updated: May 15, 2026

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

Adoptive T-cell transfer in melanoma.

Orit Itzhaki1, Daphna Levy, Dragoslav Zikich

  • 1Ella Institute for Melanoma, Sheba Medical Center, 52621 Ramat Gan, Israel.

Immunotherapy
|December 22, 2012
PubMed
Summary

Adoptive cell transfer (ACT) immunotherapy shows significant promise for metastatic melanoma, offering durable disease control and potential cures. This approach involves reinfusing expanded tumor-infiltrating T lymphocytes, with ongoing advancements exploring genetic modifications for broader cancer treatment.

More Related Videos

Generation of Induced Pluripotent Stem Cells from Human Melanoma Tumor-infiltrating Lymphocytes
10:03

Generation of Induced Pluripotent Stem Cells from Human Melanoma Tumor-infiltrating Lymphocytes

Published on: November 11, 2016

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

Related Experiment Videos

Last Updated: May 15, 2026

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

Generation of Induced Pluripotent Stem Cells from Human Melanoma Tumor-infiltrating Lymphocytes
10:03

Generation of Induced Pluripotent Stem Cells from Human Melanoma Tumor-infiltrating Lymphocytes

Published on: November 11, 2016

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

Area of Science:

  • Oncology
  • Immunology
  • Cell Therapy

Background:

  • Metastatic melanoma remains a significant challenge in cancer treatment.
  • Immunotherapy, particularly adoptive cell transfer (ACT), offers a promising therapeutic avenue.
  • Tumor-infiltrating lymphocytes (TILs) are key components in effective ACT strategies.

Purpose of the Study:

  • To summarize current ACT strategies for metastatic melanoma.
  • To highlight recent advancements in ACT for melanoma treatment.
  • To explore potential combinations of ACT with other therapies.

Main Methods:

  • Ex vivo expansion of autologous antitumor reactive lymphocytes.
  • Reinfusion of expanded lymphocytes into lymphodepleted patients.
  • Administration of Interleukin-2 (IL-2) to support lymphocyte activity.
  • Genetic modification of T lymphocytes with tumor-specific T cell receptors or chimeric antigen receptors (CARs).

Main Results:

  • ACT with tumor-infiltrating T lymphocytes achieves objective clinical responses in 50-72% of patients.
  • Complete responses range from 10-40%, indicating significant efficacy.
  • Durable disease control and long progression-free survival are observed.
  • Curative potential is suggested by long-term disease absence in complete responders.

Conclusions:

  • ACT, especially using tumor-infiltrating T lymphocytes, is a highly effective immunotherapy for metastatic melanoma.
  • Ongoing research into genetically modified T cells broadens the application of ACT to other cancers.
  • Future directions include combining ACT with other therapeutic modalities to enhance outcomes.